« Return to News | Study Conduct

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009 07:19 AM

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

For phase II to IV clinical trials launched in Q2, 12,338 patients were enrolled—nearly the same as the 12,000 enrolled in the same quarter last year.

Clinical trials conducted in Russia were conducted by sponsor companies from 16 countries, with the most being initiated by Russian companies, followed by companies based in the U.S., Switzerland, Germany, UK and Japan and others.

Seventy-five percent of the studies in Q2 2009 were conducted in the following six therapeutic areas: cardiovascular, oncology, endocrinology, respiratory, infectious diseases and neurology.

The top five sponsor companies initiating the most studies in Russia during Q2 were, in order: Novartis, Pfizer, Bristol-Myers Squibb, Eli Lilly and Merck.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.